Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre sold 12,000 shares of the company’s stock in a transaction on Friday, November 20th. The stock was sold at an average price of $38.76, for a total transaction of $465,120.00. Following the completion of the transaction, the senior vice president now directly owns 142,689 shares of the company’s stock, valued at approximately $5,530,625.64. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.
Shares of NASDAQ HALO opened at $39.45 on Friday. The firm’s 50-day moving average price is $31.60 and its 200-day moving average price is $27.59. The company has a current ratio of 18.49, a quick ratio of 17.34 and a debt-to-equity ratio of 3.98. The stock has a market capitalization of $5.33 billion, a price-to-earnings ratio of 246.56 and a beta of 1.57. Halozyme Therapeutics, Inc. has a 12-month low of $12.71 and a 12-month high of $41.26.
Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Monday, November 2nd. The biopharmaceutical company reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.05. The firm had revenue of $65.30 million for the quarter, compared to analysts’ expectations of $59.35 million. Halozyme Therapeutics had a net margin of 10.78% and a return on equity of 24.29%. The business’s revenue was up 41.3% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.17) EPS. On average, equities analysts predict that Halozyme Therapeutics, Inc. will post 0.85 EPS for the current fiscal year.
Several research analysts recently weighed in on HALO shares. TheStreet raised shares of Halozyme Therapeutics from a “c+” rating to a “b” rating in a report on Tuesday, November 3rd. Piper Sandler upped their target price on shares of Halozyme Therapeutics from $31.00 to $37.00 and gave the stock an “overweight” rating in a report on Monday, November 2nd. Wells Fargo & Company upped their target price on shares of Halozyme Therapeutics from $39.00 to $60.00 and gave the stock an “overweight” rating in a report on Monday, November 16th. Zacks Investment Research raised shares of Halozyme Therapeutics from a “sell” rating to a “hold” rating and set a $30.00 price objective for the company in a report on Tuesday, October 13th. Finally, BidaskClub raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 17th. Four investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $33.50.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Recommended Story: Beige Book
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.